Exploring Bi-Specific Antibodies in Lymphoma Treatment

Discussion on the challenges of selecting the most suitable bi-specific antibody for lymphoma treatment, considering dosing intervals, therapy durations, patient preferences, and therapy sequencing. Emphasis on shared decision-making, therapy delivery considerations, future prospects, and emerging risks in utilizing bi-specific antibodies.